Lipocine LPCN
NASDAQ LPCN
$1.62 +0.00 (+0.00%)
As of: Oct 21, 2026 · 9:37 AM EDT

Lipocine (LPCN) Restructuring Costs (2016)

Updated

Lipocine (LPCN) recorded Restructuring Costs of $343,402 in Q4 2016, down 10.9% from the prior quarter.

Analysis

Lipocine (LPCN) Restructuring Costs (2016) Analysis & Trends

For FY2016, Lipocine reported Restructuring Costs of $728,635.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,140.41 Bn 1,108.99 Bn 19.71 Bn
2 Johnson & Johnson 618.57 Bn 537.10 Bn 17.26 Bn
3 AbbVie 509.95 Bn 483.06 Bn 12.70 Bn
4 Merck 366.63 Bn 321.01 Bn 12.21 Bn
5 Novartis Ag 298.47 Bn 262.46 Bn 11.24 Bn
6 Astrazeneca 263.21 Bn 236.89 Bn 12.86 Bn
7 Amgen 236.71 Bn 192.11 Bn 7.24 Bn
8 Gilead Sciences 193.05 Bn 167.25 Bn 6.22 Bn
9 Pfizer 171.45 Bn 118.10 Bn 10.94 Bn
10 Lipocine 8.77 Mn -58.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 343,402.00
Sep 30, 2016 385,233.00
API Access

Lipocine Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=LPCN&period=max&api_key=YOUR_API_KEY